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Evidence supports a role of 17β-estradiol (E2) in carcinogenesis and the large majority 
of breast carcinomas are dependent on estrogen. The anti-estrogen tamoxifen (TAM) 
is widely used for both treatment and prevention of breast cancer; however, it is also 
carcinogenic in human uterus and rat liver, highlighting the profound complexity of its 
actions. The nature of E2- or TAM-induced chromosomal damage has been explored using 
relatively high concentrations of these agents, and only some numerical aberrations 
and chromosomal breaks have been analyzed. This study aimed to determine the effects 
of low doses of E2 and TAM (10−8 mol L−1 and 10−6 mol L−1 respectively) on karyotypes 
of MCF7, T47D, BT474, and SKBR3 breast cancer cells by comparing the results of 
conventional karyotyping and multi-FISH painting with cell proliferation. Estrogen 
receptor (ER)-positive (+) cells showed an increase in cell proliferation after E2 treatment 
(MCF7, T47D, and BT474) and a decrease after TAM treatment (MCF7 and T47D), whereas 
in ER− cells (SKBR3), no alterations in cell proliferation were observed, except for a 
small increase at 96 h. Karyotypes of both ER+ and ER− breast cancer cells increased 
in complexity after treatments with E2 and TAM leading to specific chromosomal 
abnormalities, some of which were consistent throughout the treatment duration. This 
genotoxic effect was higher in HER2+ cells. The ER−/HER2+ SKBR3 cells were found to 
be sensitive to TAM, exhibiting an increase in chromosomal aberrations. These in vitro 
results provide insights into the potential role of low doses of E2 and TAM in inducing 
chromosomal rearrangements in breast cancer cells.
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Introduction
17β-estradiol (E2) is the main estrogenic hormone 
that through the estrogen receptors (ER) acts on the 
mammary gland regulating a wide variety of biological 
processes including differentiation, cell proliferation, and 
development at puberty and during sexual maturity. E2 
may be procancerogenic by inducing (i) ER-mediated cell 
proliferation, (ii) gene mutation through a cytochrome 
P450-mediated metabolic activation, and (iii) aneuploidy 
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(Russo & Russo 2006), through overexpression of 
Aurora-A (Aur-A), a centrosome kinase, and centrosome 
amplification (Li et al. 2004). In addition, in both ER+ and 
ER− breast cancer cells, E2 may induce chromatin structural 
changes through the estrogen-related receptors (ERR) (Hu 
et al. 2008). Although high levels of E2 are implicated in 
breast cancer in postmenopausal women (Bernstein & 
Ross 1993), constant low E2 concentrations, in the range 
of picograms, are sufficient to increase breast cancer risk in 
premenopausal women (Chetrite et al. 2000).
Tamoxifen (TAM) is a non-steroidal anti-estrogen with 
partial agonistic activity, extensively used in the treatment 
of ERα-positive breast cancer. Response to TAM is frequently 
of limited duration due to the development of resistance 
(Pearce & Jordan 2004, International Breast Cancer Study 
et  al. 2006). Although ERα positivity is a well-established 
predictor of response to TAM and ERα-negative patients 
are considered nonresponders, it is known that 5–10% of 
ERα-negative tumors do benefit from adjuvant TAM 
treatment (McGuire 1975, Early Breast Cancer Trialists’ 
Collaborative Group 1992, 1998, Early Breast Cancer Trialists’ 
Collaborative Group et al. 2011, Gruvberger-Saal et al. 2007).
Paradoxically, it has been reported that TAM possesses 
a high mutagenic potential causing chromosome ruptures 
in animal models (Mizutani et al. 2004). However, data on 
type and frequency of chromosome abnormalities induced 
by TAM are scant (Mizutani et  al. 2004). In particular, 
cytogenetic studies about the effects of low doses of TAM, 
as it is suggested for treatment of pre-invasive low-grade 
breast lesions (e.g., low-grade ductal carcinomas in situ 
or lobular intraepithelial neoplasia), are limited (Kedia-
Mokashi et al. 2010). The nature of E2- or TAM-induced 
chromosomal damage has been explored using relatively 
high concentrations of these agents, and only some 
numerical aberrations and chromosomal breaks have 
been analyzed (Tsutsui & Barrett 1997, Mizutani et  al. 
2004, Quick et al. 2008, Kedia-Mokashi et al. 2010).
The aim of this study was to determine the effects of 
low doses of E2 and TAM on chromosomal rearrangements 
by comparing the results of conventional karyotyping 
and multicolor fluorescence in situ hybridization (M-FISH) 
painting with cell proliferation activity of human breast 
cancer cells with differential expression of ER and HER2.
Materials and methods
Cell lines
The human breast cancer cell lines MCF7 and T47D 
(ER+/progesterone receptor (PR)+/HER2−), BT474 
(ER+/PR+/HER2+), and SKBR3 (ER−/PR−/HER2+) were 
obtained from the American Type Culture Collection 
(ATCC) in March 2010. Cell lines were expanded and 
stocked at −80°C and cells obtained from these stocks 
were thawed and used for the experiments. At the end 
of experiments, short tandem repeat (STR) profiles were 
performed to confirm the authentication of the cell lines 
used. All experiments were carried out in each cell line at 
passages (P) below 30.
MCF7 (P19), T47D (P20), and SKBR3 (P16) were 
cultured in RPMI-1640 medium (Sigma), whereas BT474 
(P18) was cultured in DMEM medium (Sigma). All culture 
media were supplemented with 10% fetal bovine serum 
(FBS) (Sigma), antibiotic–antimycotic solution (1X) 
(Sigma), and l-glutamine (2 mM) (Invitrogen GmbH). Cells 
growing in 75 cm2 flasks were maintained at 37°C and 5% 
CO2. The absence of contamination with mycoplasma 
was demonstrated by PCR assay.
E2 and TAM treatment
In order to remove endogenous serum steroids and 
exclude the weak estrogen agonistic activity of phenol red 
(Berthois et al. 1986), 48 h before the addition of E2 (E2758; 
Sigma) and TAM (T5648; Sigma) cells were washed with 
5 mL phosphate-buffered saline (PBS) and then switched 
to phenol red-free RPMI-1640 (Sigma) containing 10% 
charcoal-stripped FBS (Sigma). E2 and TAM were dissolved 
in absolute ethanol and diluted in the media at 10−8 mol L−1 
and 10−6 mol L−1, respectively, and then added to the 
culture medium at 24, 48, and 96 h. These concentrations 
have been demonstrated to be the lowest to induce an 
effect on the architecture of the cytoskeleton in breast 
cancer cells in vitro (Sapino et al. 1986).
Cells without treatment at 24 h (T24 h) and at 96 h 
(T96 h) were used as controls.
Proliferation assay
Cells were seeded at a density of 2.5–5 × 103 cells per 
100 μL of phenol red-free medium in a 96 multi-well 
plate and after 24 h were treated with E2 and TAM 
for 24, 48, and 96 h. At the end of each treatment, cell 
proliferation was assessed using the cell proliferation 
ELISA kit, BrdU (Roche Diagnostics Deutschland GmbH). 
Measurement of absorbance was performed by using a 
MultiSkan Bichromatic reader (Labsystems, Midland, 
Canada) against a background control as blank. Each 
treatment was performed in 24 replicates and expressed as 
means ± standard deviation (s.d.).
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Metaphase spreads and G-banding
To determine whether E2 and TAM treatment resulted 
in the induction of chromosomal abnormalities, we 
performed conventional and molecular cytogenetic 
analysis in parallel with the evaluation of cell proliferation. 
Metaphases were obtained by using standardized 
harvesting protocols in order to perform conventional 
and molecular cytogenetic analysis (multi-FISH and 
FISH). Briefly, colcemid solution (0.03 μg/mL) (Sigma) was 
added to cultures 2.5 h before cell harvesting; cells were 
then treated with hypotonic solution, fixed three times 
with Carnoy’s fixative (3:1 methanol to acetic acid), and 
spread on glass. For analysis of chromosomal alterations, 
the slides were banded with G-banding. Glass slides were 
baked at 70°C for 24 h, incubated in HCl, and placed 
in 2xSSC buffer before treatment with Wright’s stain. 
Metaphase image acquisition and subsequent karyotyping 
were performed using a Nikon microscope with the 
cytogenetic software CytoVision System (Applied Imaging, 
Santa Clara, CA, USA). According to the International 
System of Cytogenetic Nomenclature (Shaffer et al. 2013) 
“The general rule in tumor cytogenetics is that only the 
clonal chromosomal abnormalities should be reported”, 
whereas a minimal number of metaphases to be analyzed 
is not indicated. In this respect, we indicated only those 
alterations present in at least two metaphases, which is 
indicative of clonal chromosomal alterations (Shaffer 
et  al. 2013). Based on these premises, we systematically 
analyzed 100 metaphases in order to establish the 
frequency of ploidy after treatments, by counting the 
number of chromosomes. As a second step, out of these 
metaphases, only those with good morphology and proper 
separation of chromosomes were analyzed by M-FISH and 
G-banding (between 11 and 26). Chromosome aberrations 
were described according to the International System of 
Human Cytogenetic Nomenclature (ISCN 2013) (Shaffer 
et al. 2013).
Multi-FISH (M-FISH)
M-FISH was performed with the aim of identifying 
complex chromosomal rearrangements. The 
probe cocktail containing 24 differentially labeled 
chromosome-specific painting probes (24xCyte kit 
MetaSystems, Altlussheim, Germany) was used according 
to the protocol recommended by Human Multicolor 
FISH kit (MetaSystems, Altlussheim, Germany). Briefly, 
the slides were incubated at 70°C in saline solution 
(2xSSC), denatured in NaOH, dehydrated in ethanol 
series, air-dried, covered with 10 μL of probe cocktail 
(denatured), and hybridized for 2 days at 37°C. Slides 
were then washed with post-hybridization buffers, 
dehydrated in ethanol series, and counterstained with 
10 μL of DAPI/antifade. Signal detection and subsequent 
metaphase analysis were done using the Metafer system 
and Metasytems’ ISIS software (software for spectral 
karyotypes) (Carl Zeiss, Metasystems, GmbH, Germany) 
(Rondon-Lagos et al. 2014a,b).
Immunohistochemistry (IHC)
Immunohistochemistry for ER and PR was carried out 
on MCF7, T47D, BT474, and SKBR3 cells at baseline and 
treated with E2 (10−8 mol L−1) and TAM (10−6 mol L−1) for 
24, 48, and 96 h. At each time point, cells were harvested, 
formalin-fixed, and paraffin-embedded according to 
standard procedures. Sections of the representative cell 
block were cut at 3 μm and mounted on electrostatically 
charged slides. Immunohistochemistry was performed 
using an automated immunostainer (Ventana BenchMark 
XT AutoStainer; Ventana Medical Systems, Tucson, 
AZ, USA) with antibodies against ER (Clone SP1, 
prediluted, Ventana) and PR (Clone 1A6, 1:50 diluted; 
Leica Biosystems). Positive and negative controls were 
included for each immunohistochemical run. IHC slides 
were scanned by using the Aperio system (ScanScope CS 
System, Vista, CA, USA) for automated counting. To ensure 
the reliability of the automatic assessment, stainings were 
reviewed by two pathologists (A S and C M).
Data analysis
The profile of numeric and structural chromosomal 
changes observed after treatments was determined 
in comparison with the control. Student’s t-test was 
performed to compare cell proliferation of treated cell lines 
with untreated cell lines. Fisher’s exact test was applied to 
compare conventional and molecular cytogenetic results 
from treated cell lines with the results from control cell 
lines (differences in single chromosomal alterations 
between control and treated cells). In addition, Pearson’s 
χ2 test was used to investigate a possible association 
between occurrence of specific chromosomal aberrations 
at each time point and effect on proliferation. The 
coefficient of variation, CV (=100 × standard deviation/
mean), was used to calculate the variability in the 
frequency of new chromosomal alterations, observed after 
E2 and TAM treatments (24, 48, and 96 h). P values <0.05 
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were considered as statistically significant. All statistical 
analyses were performed using the SPSS v.20 program.
Results
General effects on chromosomes induced by low doses 
of E2 and TAM
Control cells harbored the same alterations previously 
reported (Rondon-Lagos et  al. 2014a,b). Both E2 and 
TAM treatments rapidly induced de novo chromosomal 
alterations.
The frequency of new chromosomal alterations 
changed along E2 and TAM treatments for all cell 
lines, and while the frequency of some chromosomal 
abnormalities remained constant along treatments, other 
increased or decreased (CV range: 3–96%) (Fig.  1 and 
Supplementary  Table  1, see section on supplementary 
data given at the end of this article). This variability is 
not surprising, considering that genetic diversification, 
clonal expansion, and clonal selection are events widely 
reported in cancer and also associated with therapeutic 
interventions (Greaves & Maley 2012).
More in detail, compared with control cells (T24 h 
and T96 h without treatment), low doses of E2 increased 
the chromosome ploidy in all cell lines (Table  1A), 
whereas TAM was effective on ploidy only in HER2+ 
cell lines (Table  1B). Some of the alterations were 
observed in more than one cell line and were induced 
by both E2 and TAM (Fig. 2 and Supplementary Table 2). 
In Fig.  3, the chromosomal aberrations induced or 
increased after E2 or TAM treatments as compared with 
control cells are represented. Low doses of E2 produced 
Figure 1
Frequency of chromosomal alterations observed de novo after E2 and TAM treatments. The frequency of each chromosomal alteration is indicated along 
the treatments (24, 48, and 96 h) using a color code for each category. (A) MCF7 cells. (B) T47D cells. (C) BT474 cells. (D) SKBR3 cells. A full colour version 
of this figure is available at http://dx.doi.org/10.1530/ERC-16-0078. 
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numerical alterations represented mainly by gain of 
whole chromosomes in all cell lines. Low doses of both 
E2 and TAM induced de novo structural aberrations such 
as isochromosomes (i) in BT474 and SKBR3 cells and 
dicentric (dic) chromosomes in T47D and BT474 cells. 
Both treatments increased derivative (der) chromosomes 
in HER2+ cells only, whereas additional material of 
unknown origin (add) was a de novo observation only in 
T47D after E2 treatment.
Many of the altered chromosomal regions in the 
cell lines analyzed contain important genes involved in 
breast cancerogenesis including BCAR3 (1p22), CENPF 
(1q41), ENAH (1q42), and AKT3 (1q44) associated with 
aneuploidy, chromosomal instability, and anti-estrogen 
resistance (Nakatani et al. 1999, Di Modugno et al. 2006, 
O’Brien et  al. 2007); FHIT, FOXP1, and LRIG1 on 3p14 
correlated with chromosomal instability and anti-estrogen 
resistance (Campiglio et  al. 1999, Banham et  al. 2001, 
Table 1 Percentage of cells with polyploidy in MCF7, T47D, BT474, and SKBR3 cell lines. (A) Control and E2 treated. (B) Control 
and TAM treated. A hundred metaphases were analyzed for both control and for each of the treatments with E2 and TAM.
Treatments
MCF7 T47D BT474 SKBR3
4n >4n 3n >3n 4n >4n 4n >4n
A
Control 98 2 96 4 100 0 81 19
E2. 24 h 85 15 87 13 88 12 63 37
E2. 48 h 80 20 78 22 77 23 52 48
E2. 96 h 61 39 67 33 70 30 50 50
B
Control 98 2 96 4 100 0 81 19
TAM. 24 h 97 3 85 15 94 6 24 76
TAM. 48 h 99 1 98 2 98 2 24 76
TAM. 96 h 99 1 100 0 84 16 30 70
New chromosomal abnormalities
Treatment with E2. 10-8 mol L-1 Treatment with TAM. 10-6 mol L-1 
MCF7 T47D BT474 SKBR3 MCF7 T47D BT474 SKBR3 
+X 
+1 
del(1)(p31) 
chrb(1)(p13),chte(1)(q21),del(1)(q11),+5 
del(1)(p22),del(3)(p13) 
dic(1;19)(p11;q13),i(1)(q10) 
+3 
add(3)(p21),der(3)t(3;8)(p14;?) 
add(3)(q13),del(11)(p15) 
+6 
-6 
-7 
-8 
+8 
+9 
der(6)dup(6)(p25p?),del(7)(q11.2) 
add(7)(q36),del(7)(p22),del(7)(q21),del(7)(q32) 
der(7)t(7;14)(p11;q11.2),der(19)t(10;19)(q11;q13)  
der(7)t(7;20)(p22;?)t(7;20)(?;?) 
dic(7;7)(p15;p15) 
dic(7;?)(q36;?),der(9)t(7;9)(?;p24),del(11)(p11.2) 
add(8)(p23) 
der(8)t(8;17)(p23;?)t(6;17),-12,der(15;15) 
del(9)(q21),+10,del(10)(p11.2),+15 
der(9)t(9;21)(p24;?)t(8;21)(?;?)  
add(11)(q23),der(17)t(17;21)(q24;?) 
der(11)t(4;11)(?;p15) 
-14 
+14 
+16 
-17 
+19 
der(19)t(13;19)(q?;q13) 
+20 
+21 
der(22)t(20;22)(?;q13)t(16;20)(?;?) 
 Alterations induced by E2 and/or TAM 
 Alterations increased by E2 and/or TAM  
 Alterations reduced by E2 and/or TAM  
 Alterations not modified by E2 or TAM  
 Absence of that chromosomal alteration 
Figure 2
Clonal chromosomal abnormalities induced by E2 
and TAM in four breast cancer cell lines at each 
treatment time point. The presence of a given 
chromosomal alteration after E2 and/or TAM 
treatment in one or more cell lines is color coded 
according to the legend at the bottom. A full 
colour version of this figure is available at http://
dx.doi.org/10.1530/ERC-16-0078.
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Ljuslinder et al. 2005); AKAP9 (7q21), DMTF1 (7q21), and 
HIPK2 (7q32) involved in the assembly of protein kinases 
to the centrosome and in growth arrest (Edwards & Scott 
2000, Sreeramaneni et  al. 2005, Pierantoni et  al. 2007); 
E2F1 (20q11.22) and MAPRE1 (20q11.1-11.23) involved 
in the regulation of the mitotic cell division process, 
regulation of microtubule dynamic instability, and in cell 
cycle control (Stender et al. 2007), among others (Table 2).
Combined effects on cell proliferation and  
chromosomal alterations
We then more specifically analyzed the chromosomal 
alterations in comparison with the effects on proliferation 
induced by E2 and TAM in each cell line. Although we 
did not observe a specific pattern of chromosomal 
aberrations that significantly correlated with either 
increased or decreased proliferation rates across cell lines, 
single aberrations significantly correlated with increase 
or decrease of proliferation within each cell line, as 
detailed below.
In MCF7 cell line, as expected, E2 treatment 
significantly stimulated cell proliferation (P < 0.0001, 
Student’s t-test; Fig.  4A) and induced more structural 
than numerical chromosomal alterations (P ≤ 0.05, 
Fisher’s exact test; Fig. 2, Supplementary Tables 2, 3 and 
4). However, only a statistically significant increase in 
nullisomy of chromosome 18 and 20 (P < 0.01) together 
with del(7)(q21) and del(7)(q32) was constantly observed 
at all treatment time points (Figs 2 and 4A, Supplementary 
Tables 3 and 4).
TAM treatment inhibited significantly MCF7 cell 
proliferation (P < 0.01) (Fig.  4B). Eleven chromosomes 
(1, 2, 6, 7, 8, 10, 11, 17, 15, 19, and 20) varied in their copy 
number, but most of these alterations, except for +1 and 
−6, were observed only in one of the treatment time points 
and were considered as sporadic (Supplementary Table 3). 
As compared with control cells, six additional complex 
chromosomal aberrations, del(1)(p22), del(3)(p13), der(7)
t(7;20)(p22;?)t(7;20)(?;?), add(8)(p23), der(9)t(9;21)(p24;?)
t(8;21)(?;?), and der(11)t(4;11)(?;p15) (Figs 2, 4B, 5A and 
Supplementary Table  2), were identified and constantly 
present at each time point. In addition, der(11)t(4;11)
(?;p15) was observed in both E2- and TAM-treated cells. An 
increase in the frequency of two pre-existing alterations 
del(7)(q11.2) and del(12)(p11.2) was also observed after 
both E2 and TAM treatment (Supplementary Table 4).
T47D cells responded to E2 treatment with the 
highest growth advantage at 96 h (Fig.  6A). This effect 
corresponded to a more complex karyotype of E2-
stimulated cells than control cells with the following 
additional alterations, +3, −7, −8, der(11)t(4;11)
(?;p15), −14, +16, and der(17)t(17;21)(q24;?) (P < 0.01), 
observed at least at two time points (Figs 2, 5B, 6A and 
Supplementary Table  2). In analogy to MCF7 cells, an 
increase in the frequency of some pre-existing numerical 
alterations was observed after both treatments in T47D 
cells (Supplementary Table 5).
The effect of TAM on cell growth inhibition was much 
lower than that observed in MCF7 cells and disappeared at 
96 h (Fig. 6B). As compared with untreated controls, only 
three additional numerical alterations were constantly 
present (+6, −14, and −17) (P < 0.01, Fisher’s exact test) 
after TAM (Fig.  6B, Supplementary Tables  5 and 6). On 
the contrary, some chromosomal rearrangements present 
in the control cells could not be observed after E2 and 
TAM treatment (Supplementary Table 6). In T47D, both 
E2 and TAM induced loss of chromosomes 7, 8, and 14, 
whereas an additional chromosome 19 was induced by 
both treatments in T47D and SKBR3 cells.
In BT474 cells, both E2 and TAM treatments induced 
two peaks of proliferation at 24 and 96 h. G-banding 
and M-FISH analyses of both E2- and TAM-treated 
BT474 cells identified the same new chromosomal 
complex rearrangements der(3)t(3;8)(p14;?), der(8)
Figure 3
Total number of chromosomal aberrations induced after E2 (A) and TAM 
(B) treatment at 24, 48, and 96 h in MCF7, T47D, BT474, and SKBR3 cell 
lines. Numerical chromosomal alterations: gains and losses. Structural 
chromosomal alterations: add, additional material of unknown origin; 
del, deletion; der, derivative chromosome; dic, dicentric chromosome;  
i, isochromosome. A full colour version of this figure is available at  
http://dx.doi.org/10.1530/ERC-16-0078.
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t(8;17)(p23;?)t(6;17)(?;?), and der(15;15)(q10;q10) 
at each time point (Figs  2, 5C, 7 and Supplementary 
Table 2). Additional new rearrangements were observed 
after E2 (Fig. 7A, Supplementary Tables 7 and 8) or after 
TAM treatment (Fig.  7B) at least at two time points. 
An increase in the frequency of some preexisting 
chromosomal alterations (P ≤ 0.01) was also observed 
(Supplementary Tables 7 and 8).
Finally, in SKBR3 (ER−/HER2+), only 96 h of E2 and 
TAM treatment significantly increased cell proliferation 
(P < 0.006 and P < 0.024) (Fig.  8), as compared with 
controls. However, de novo chromosomal alterations were 
already observed after 24 h of treatment. SKBR3 control 
cells displayed a complex karyotype with a particularly 
high frequency of chromosome 1 aberrations. After 
24 h of E2 and TAM treatment, the karyotype became 
even more complex with the appearance of new 
chromosome 1 abnormalities, such as for instance 
dic(1;19)(p11;q13) and i(1)(q10) (P < 0.05) (Figs  2, 
5D, 8A, B and Supplementary Table  2). A statistically 
significant increase in the frequency of some pre-existing 
chromosomal abnormalities was observed in SKBR3 as 
well (Supplementary Tables 9 and 10).
Expression of hormone receptors following treatment
IHC analysis showed that ER levels remained unchanged 
after E2 and TAM addition in MCF7, T47D, and SKBR3 
cells, whereas in BT474 cells we observed an increase in 
both ER and PR expression after TAM treatment in parallel 
with an increase in proliferation (all time points; data not 
shown). These results support the hypothesis that TAM 
could play an estrogen agonist role in ER+/HER2+ cells 
(BT474), as it has been previously suggested (Pietras & 
Marquez-Garban 2007, Chang 2011, Kumar et  al. 2011) 
and shown in other cell line models (Shou et al. 2004). In 
addition, increased PR expression in human breast cancers 
has been associated with TAM resistance (Cui et al. 2005).
E2 addition increased PR expression also in the 
other ER+ cell lines (MCF7 and T47D). In contrast, after 
TAM treatment, a reduced PR expression was observed 
in MCF7 and T47D cells (data not shown). This is in 
line with previous observations showing that when 
estradiol is acting, TAM is not able to increase the level 
of occupied estrogen receptors and it acts as an anti-
estrogen by decreasing the high level of progesterone 
receptors previously induced by estradiol (Castellano-
Diaz et al. 1989).
Discussion
Short-term endocrine treatment has been proposed as an 
alternative to long-term neoadjuvant therapy to assess 
tumor response (Dowsett et  al. 2007). In addition, low 
doses of TAM have been proposed for chemoprevention 
in women at high risk of developing breast cancer 
(Lazzeroni et  al. 2012). Hypersensitivity to low levels of 
estrogen has been suggested as a potential mechanism of 
endocrine therapy resistance (Johnston & Dowsett 2003). 
In addition, residual amounts of estrogen may still be 
present after treatment with aromatase inhibitors, which 
function by reducing estrogen biosynthesis (Dowsett 
Figure 4
Effects of E2 (A) and TAM (B) treatment for 24, 48, and 96 h on 
proliferation and corresponding chromosomal alterations in MCF7 cells. 
Error bars represent mean standard deviation of 24 separate experiments. 
Chromosomal abnormalities induced at each treatment time point are 
indicated. A full colour version of this figure is available at http://dx.doi.
org/10.1530/ERC-16-0078.
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1999). E2 binding to tubulin may induce a cell cycle arrest 
in G2/M and generate chromosomal instability (Sato et al. 
1992, Sattler et al. 2003, Azuma et al. 2009, Lee et al. 2015).
In this study, we observed that low doses of both E2 
and TAM were able to induce structural chromosomal 
aberrations (deletions, isochromosomes, translocations, 
and dicentric chromosomes) in both ER+ and ER− breast 
cancer cells.
Dicentric chromosomes, which contain two 
functional centromeres, can lead to extensive 
chromosomal rearrangements, including translocations 
with other chromosomes (Gascoigne & Cheeseman 
2013). Chromosomal translocations, a frequent event 
observed after E2 and TAM treatment, may lead to the 
production of tumor-specific fusion proteins, which are 
often transcription factors (Rabbitts 1994). For example, 
der(11)t(4;11)(?;p15) was observed in both E2- and TAM-
treated MCF7 cells and in E2-treated T47D. Several genes 
are located in the imprinted gene domain of 11p15.5, an 
important tumor-suppressor gene region (Hu et al. 1997).
While some complex chromosomal alterations were 
consistent throughout the treatments, other disappeared. 
The above could be related with the instability of such 
alterations. After treatment, unstable chromosomal 
alterations could be randomly fused to form more complex 
chromosomal rearrangements including translocations, 
dicentric chromosomes, and duplications (Shen 2013, 
Zhang et al. 2013). Another possible explanation, which 
can be strictly connected to the previous, is the possibility 
of clonal selection of the fittest clone (Heng et al. 2006, 
Liu et al. 2014, Dayal et al. 2015).
When chromosomal alterations were analyzed with 
respect to proliferation, some specific patterns within each 
cell line were observed. For instance, T47D cells showed a 
poorer response to TAM compared with MCF7 cells and 
mainly displayed numerical chromosomal alterations 
following treatment. The ER+/HER2+ BT474 cells showed 
the highest increase in cell proliferation after 24 h of 
treatment with both E2 and TAM compared with control 
cells. Cell growth increase after TAM treatment may 
indicate an estrogen agonist activity, possibly enhanced 
by the co-expression of ER and HER2 (Pietras & Marquez-
Garban 2007, Chang 2011, Kumar et al. 2011). Indeed, the 
cross talk between ER pathways and growth factor receptor 
Figure 5
Representative images of chromosomal 
abnormalities observed throughout the 
treatment duration with either E2 or TAM. 
(A) MCF7 cells, (B) T47D cells, (C) BT474 cells, and 
(D) SKBR3 cells. Rearranged chromosomes are 
visualized by G-banding technique on the left 
and by M-FISH on the right. The chromosomes 
involved in the rearrangement are numbered on 
the right hand side of the chromosomes. A full 
colour version of this figure is available at  
http://dx.doi.org/10.1530/ERC-16-0078.
645Research M Rondón-Lagos et al. Breast cancer cell karyotypes, 
E2 and tamoxifen
En
d
o
cr
in
e-
R
el
at
ed
 C
an
ce
r
DOI: 10.1530/ERC-16-0078
http://erc.endocrinology-journals.org © 2016 Society for Endocrinology
Printed in Great Britain
Published by Bioscientifica Ltd.
23:8
pathways (EGFR, IGF-1, and HER2) has been involved in 
cell proliferation, survival, and resistance to endocrine 
therapy (TAM) in breast cancer (Yager & Davidson 2006, 
Pietras & Marquez-Garban 2007, Chang 2011). However, 
in our study, after 48 h of TAM treatment cell proliferation 
decreased and increased again at 96 h. This decrease/increase 
may be explained through a clonal selection, with survival 
of those cells that acquired chromosomal abnormalities 
fostering proliferative and survival advantages.
As expected, our results confirm that the induction and 
inhibition of cell proliferation by E2 and TAM, respectively, 
is dependent on the presence of ER. However, in the 
ER−/HER2+ SKBR3 cells, these agents induced a high 
frequency of chromosomal abnormalities and a small 
increase in proliferative activity at 96 h of treatment. Both 
effects may be due to the presence of the G protein-coupled 
receptor 30 (GPCR30), an estrogen transmembrane receptor, 
which modulates both rapid non-genomic and genomic 
transcriptional events of estrogen (Thomas et  al. 2005, 
Chen & Russo 2009, Li et  al. 2010, Cheng et  al. 2011). 
On the other hand, E2 may induce chromatin structural 
Figure 7
Effects of E2 (A) and TAM (B) treatment for 24, 48, and 96 h on 
proliferation and corresponding chromosomal alterations in BT474 cells. 
Error bars represent mean standard deviation of 24 separate 
experiments. Chromosomal abnormalities induced at each treatment 
time point are indicated. A full colour version of this figure is available at 
http://dx.doi.org/10.1530/ERC-16-0078.
Figure 6
Effects of E2 (A) and TAM (B) treatment for 24, 48, and 96 h on 
proliferation and corresponding chromosomal alterations in T47D cells. 
Error bars represent mean standard deviation of 24 separate experiments. 
Chromosomal abnormalities induced at each treatment time point are 
indicated. A full colour version of this figure is available at http://dx.doi.
org/10.1530/ERC-16-0078.
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changes in both ER+ and ER− breast cancer cells through 
ERR (Hu et  al. 2008). The ability of estrogens and its 
metabolites (catechol  estrogens) to induce mutations 
in cancer cells has been demonstrated both in vivo and 
in vitro (Liehr 2000, Yager 2015), being observed that 
estrogens induce overexpression of the Aurora A and B 
genes (Li et  al. 2004), cause genomic instability (Barrett 
et  al. 1981, Tsutsui & Barrett 1997, Ahmad et  al. 2000, 
Jeruss et al. 2003, Lam et al. 2011, Yager 2015), and induce 
chromosomal aberrations, thus confirming its properties 
as mutagenic and carcinogenic factor. Along the same 
lines, in luminal breast tumors, up-regulation of ER signal 
pathway has been associated with cell proliferation, cell 
survival, and therapy resistance (Yager & Davidson 2006, 
Pietras & Marquez-Garban 2007, Chang 2011). Although 
factors such as local synthesis of estrogen (Fabian et  al. 
2007), autocrine regulation of cell proliferation (Fabian 
et al. 2007, Tan et al. 2009), and cross talk with signaling 
from other growth factors have been associated with this 
up-regulation, the mechanisms underlying the action of 
ER are still not fully understood.
In summary, our results demonstrate that low doses 
of E2 and TAM may favor the production of specific 
chromosomal abnormalities in both ER+ and ER- breast 
cancer cells. This genotoxic effect is higher in those cell 
lines with HER2 gene amplification. The induction of 
chromosomal alterations by E2 and TAM observed in vitro 
may support the contention that a careful assessment of 
the risk and the benefit of E2 and TAM administration 
should be considered. Indeed, the novel chromosomal 
rearrangements originated following E2 and TAM exposure 
may contribute to stimulate cell proliferation leading to 
survival advantages and allowing for selection of clones 
with new chromosomal abnormalities. In vivo studies that 
may help address the biological effect of such alterations 
and ascertain whether or not these may be responsible for 
treatment resistance are warranted.
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